|
1
|
Nussbaum L, Hogea LM, Călina D, Andreescu
N, Grădinaru L, Stefănescu R and Puiu M: Modern treatment
approaches in psychoses. Pharmacogenetic, neuroimagistic and
clinical implications. Farmacia. 65:75–81. 2017.
|
|
2
|
Neagu M, Caruntu C, Constantin C, Boda D,
Zurac S, Spandidos DA and Tsatsakis AM: Chemically induced skin
carcinogenesis: Updates in experimental models (Review). Oncol Rep.
35:2516–2528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gugger A, Barnhill RL, Seifert B, Dehler
S, Moch H, Lugassy C, Marques-Maggio E, Rushing JE and Mihic-Probst
D: Cutaneous melanoma with brain metastasis: Report of 193 patients
with new observations. PLoS One. 11:e01561152016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weber JS, O'Day S, Urba W, Powderly J,
Nichol G, Yellin M, Snively J and Hersh E: Phase I/II study of
ipilimumab for patients with metastatic melanoma. J Clin Oncol.
26:5950–5956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Joosse A, de Vries E, Eckel R, Nijsten T,
Eggermont AM, Hölzel D, Coebergh JW and Engel J; Munich Melanoma
Group, : Gender differences in melanoma survival: Female patients
have a decreased risk of metastasis. J Invest Dermatol.
131:719–726. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baghirov H, Snipstad S, Sulheim E, Berg S,
Hansen R, Thorsen F, Mørch Y, Davies CL and Åslund AK:
Ultrasound-mediated delivery and distribution of polymeric
nanoparticles in the normal brain parenchyma of a metastatic brain
tumour model. PLoS One. 13:e01911022018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luss AL, Kulikov PP, Romme SB, Andersen
CL, Pennisi CP, Docea AO, Kuskov AN, Velonia K, Mezhuev YO,
Shtilman MI, et al: Nanosized carriers based on amphiphilic
poly-N-vinyl-2-pyrrolidone for intranuclear drug delivery.
Nanomedicine (Lond). 13:703–715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Engin AB, Nikitovic D, Neagu M,
Henrich-Noack P, Docea AO, Shtilman MI, Golokhvast K and Tsatsakis
AM: Mechanistic understanding of nanoparticles' interactions with
extracellular matrix: The cell and immune system. Part Fibre
Toxicol. 14:222017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neagu M, Piperigkou Z, Karamanou K, Engin
AB, Docea AO, Constantin C, Negrei C, Nikitovic D and Tsatsakis A:
Protein bio-corona: Critical issue in immune nanotoxicology. Arch
Toxicol. 91:1031–1048. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piperigkou Z, Karamanou K, Engin AB,
Gialeli C, Docea AO, Vynios DH, Pavão MS, Golokhvast KS, Shtilman
MI, Argiris A, et al: Emerging aspects of nanotoxicology in health
and disease: From agriculture and food sector to cancer
therapeutics. Food Chem Toxicol. 91:42–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pinzaru I, Coricovac D, Dehelean C, Moacă
EA, Mioc M, Baderca F, Sizemore I, Brittle S, Marti D, Calina CD,
et al: Stable PEG-coated silver nanoparticles - A comprehensive
toxicological profile. Food Chem Toxicol. 111:546–556. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wilhelm I, Molnár J, Fazakas C, Haskó J
and Krizbai IA: Role of the blood-brain barrier in the formation of
brain metastases. Int J Mol Sci. 14:1383–1411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soto MS, Serres S, Anthony DC and Sibson
NR: Functional role of endothelial adhesion molecules in the early
stages of brain metastasis. Neuro Oncol. 16:540–551. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fan J, Cai B, Zeng M, Hao Y, Giancotti FG
and Fu BM: Integrin β4 signaling promotes mammary tumor cell
adhesion to brain microvascular endothelium by inducing
ErbB2-mediated secretion of VEGF. Ann Biomed Eng. 39:2223–2241.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gorantla V, Kirkwood JM and Tawbi HA:
Melanoma brain metastases: An unmet challenge in the era of active
therapy. Curr Oncol Rep. 15:483–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fazakas C, Wilhelm I, Nagyoszi P, Farkas
AE, Haskó J, Molnár J, Bauer H, Bauer HC, Ayaydin F, Dung NT, et
al: Transmigration of melanoma cells through the blood-brain
barrier: Role of endothelial tight junctions and melanoma-released
serine proteases. PLoS One. 6:e207582011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Izraely S, Sagi-Assif O, Klein A, Meshel
T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud PO, Ateh E,
Bryant JL, et al: The metastatic microenvironment: Brain-residing
melanoma metastasis and dormant micrometastasis. Int J Cancer.
131:1071–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klein A, Schwartz H, Sagi-Assif O, Meshel
T, Izraely S, Ben Menachem S, Bengaiev R, Ben-Shmuel A, Nahmias C,
Couraud PO, et al: Astrocytes facilitate melanoma brain metastasis
via secretion of IL-23. J Pathol. 236:116–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fidler IJ: The role of the organ
microenvironment in brain metastasis. Semin Cancer Biol.
21:107–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Valiente M, Obenauf AC, Jin X, Chen Q,
Zhang XH, Lee DJ, Chaft JE, Kris MG, Huse JT, Brogi E, et al:
Serpins promote cancer cell survival and vascular co-option in
brain metastasis. Cell. 156:1002–1016. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schwartz H, Blacher E, Amer M, Livneh N,
Abramovitz L, Klein A, Ben-Shushan D, Soffer S, Blazquez R,
Barrantes-Freer A, et al: Incipient melanoma brain metastases
instigate astrogliosis and neuroinflammation. Cancer Res.
76:4359–4371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zurac S, Neagu M, Constantin C, Cioplea M,
Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et
al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in
cutaneous melanoma with regression and their possible function as
prognostic predictors. Oncol Lett. 11:3354–3360. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lupu M, Caruntu A, Caruntu C, Papagheorghe
LM, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki
M, et al: Neuroendocrine factors: The missing link in non melanoma
skin cancer (Review). Oncol Rep. 38:1327–1340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Caruntu C, Boda D, Constantin C, Caruntu A
and Neagu M: Catecholamines increase in vitro proliferation of
murine B16F10 melanoma cells. Acta Endocrinol (Buc). 4:545–558.
2014. View Article : Google Scholar
|
|
25
|
Diaconeasa A, Boda D, Solovan C, Enescu
DM, Vîlcea AM and Zurac S: Histopathologic features of Spitzoid
lesions in different age groups. Rom J Morphol Embryol. 54:51–62.
2013.PubMed/NCBI
|
|
26
|
Boda D: Cellomics as integrative omics for
cancer. Curr Proteomics. 10:237–245. 2013. View Article : Google Scholar
|
|
27
|
Nieder C, Marienhagen K, Geinitz H and
Grosu AL: Can current prognostic scores reliably guide treatment
decisions in patients with brain metastases from malignant
melanoma? J Cancer Res Ther. 7:47–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Winkler F: The brain metastatic niche. J
Mol Med (Berl). 93:1213–1220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim HY, Lee H, Kim SH, Jin H, Bae J and
Choi HK: Discovery of potential biomarkers in human melanoma cells
with different metastatic potential by metabolic and lipidomic
profiling. Sci Rep. 7:88642017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peltier J, O'Neill A and Schaffer DV:
PI3K/Akt and CREB regulate adult neural hippocampal progenitor
proliferation and differentiation. Dev Neurobiol. 67:1348–1361.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Zhang S, Yao J, Lowery FJ, Zhang
Q, Huang WC, Li P, Li M, Wang X, Zhang C, et al:
Microenvironment-induced PTEN loss by exosomal microRNA primes
brain metastasis outgrowth. Nature. 527:100–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Niessner H, Schmitz J, Tabatabai G, Schmid
MA, Calaminus C, Sinnberg T, Weide B, Eigentler KT, Garbe C,
Schittek B, et al: PI3K pathway inhibition achieves potent
antitumor activity in melanoma brain metastases in vitro and in
vivo. Clin Cancer Res. 22:5818–5828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Niessner H, Forschner A, Klumpp B,
Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J,
Tabatabai G, et al: Targeting hyperactivation of the AKT survival
pathway to overcome therapy resistance of melanoma brain
metastases. Cancer Med. 2:76–85. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Davies MA, Stemke-Hale K, Lin E, Tellez C,
Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, et al:
Integrated molecular and clinical analysis of AKT activation in
metastatic melanoma. Clin Cancer Res. 15:7538–7546. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Marzese DM, Witz IP, Kelly DF and Hoon DS:
Epigenomic landscape of melanoma progression to brain metastasis:
Unexplored therapeutic alternatives. Epigenomics. 7:1303–1311.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Satzger I, Mattern A, Kuettler U,
Weinspach D, Voelker B, Kapp A and Gutzmer R: MicroRNA-15b
represents an independent prognostic parameter and is correlated
with tumor cell proliferation and apoptosis in malignant melanoma.
Int J Cancer. 126:2553–2562. 2010.PubMed/NCBI
|
|
37
|
Hanniford D, Zhong J, Koetz L,
Gaziel-Sovran A, Lackaye DJ, Shang S, Pavlick A, Shapiro R, Berman
R, Darvishian F, et al: A miRNA-based signature detected in primary
melanoma tissue predicts development of brain metastasis. Clin
Cancer Res. 21:4903–4912. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sigalotti L, Covre A, Fratta E, Parisi G,
Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S and Maio M:
Epigenetics of human cutaneous melanoma: Setting the stage for new
therapeutic strategies. J Transl Med. 8:562010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Chen JQ, Liu JL and Tian L:
Exosomes in tumor microenvironment: Novel transporters and
biomarkers. J Transl Med. 14:2972016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Abak A, Abhari A and Rahimzadeh S:
Exosomes in cancer: Small vesicular transporters for cancer
progression and metastasis, biomarkers in cancer therapeutics.
PeerJ. 6:e47632018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Martínez-Aranda A, Hernández V, Guney E,
Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A,
Gil M, et al: FN14 and GRP94 expression are prognostic/predictive
biomarkers of brain metastasis outcome that open up new therapeutic
strategies. Oncotarget. 6:44254–44273. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Klein A, Sagi-Assif O, Meshel T, Telerman
A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DS,
et al: CCR4 is a determinant of melanoma brain metastasis.
Oncotarget. 8:31079–31091. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rolland Y, Demeule M, Fenart L and
Béliveau R: Inhibition of melanoma brain metastasis by targeting
melanotransferrin at the cell surface. Pigment Cell Melanoma Res.
22:86–98. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zbytek B, Carlson JA, Granese J, Ross J,
Mihm MC Jr and Slominski A: Current concepts of metastasis in
melanoma. Expert Rev Dermatol. 3:569–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie TX, Huang FJ, Aldape KD, Kang SH, Liu
M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3
in human melanoma promotes brain metastasis. Cancer Res.
66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tafe LJ, Gorlov IP, de Abreu FB, Lefferts
JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata
AA, et al: Implementation of a molecular tumor board: The impact on
treatment decisions for 35 patients evaluated at
Dartmouth-Hitchcock Medical Center. Oncologist. 20:1011–1018. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chowdhary M, Patel KR, Danish HH, Lawson
DH and Khan MK: BRAF inhibitors and radiotherapy for melanoma brain
metastases: Potential advantages and disadvantages of combination
therapy. OncoTargets Ther. 9:7149–7159. 2016. View Article : Google Scholar
|
|
48
|
Harding JJ, Catalanotti F, Munhoz RR,
Cheng DT, Yaqubie A, Kelly N, McDermott GC, Kersellius R, Merghoub
T, Lacouture ME, et al: A Retrospective evaluation of vemurafenib
as treatment for BRAF-mutant melanoma brain metastases. Oncologist.
20:789–797. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Larkin J, Ascierto PA, Dréno B, Atkinson
V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas
L, et al: Combined vemurafenib and cobimetinib in BRAF-mutated
melanoma. N Engl J Med. 371:1867–1876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dankort D, Curley DP, Cartlidge RA, Nelson
B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M and
Bosenberg M: Braf(V600E) cooperates with Pten loss to induce
metastatic melanoma. Nat Genet. 41:544–552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sotillo R, García JF, Ortega S, Martin J,
Dubus P, Barbacid M and Malumbres M: Invasive melanoma in
Cdk4-targeted mice. Proc Natl Acad Sci USA. 98:13312–13317. 2001.
View Article : Google Scholar : PubMed/NCBI
|
